Cargando…

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients

BACKGROUND: The EGFR and HER2 genes are located on chromosomes 7 and 17, respectively. They are therapeutic targets in some tumors. The TOP2A gene, which is located near HER2 on chromosome 17, is the target of many chemotherapeutic agents, and co-amplification of HER2 and TOP2A has been described in...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Zhiyong, Zeng, Xuan, Gao, Jie, Wu, Shafei, Wang, Peng, Shi, Xiaohua, Zhang, Jing, Liu, Tonghua
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613415/
https://www.ncbi.nlm.nih.gov/pubmed/19061514
http://dx.doi.org/10.1186/1471-2407-8-363
_version_ 1782163180055691264
author Liang, Zhiyong
Zeng, Xuan
Gao, Jie
Wu, Shafei
Wang, Peng
Shi, Xiaohua
Zhang, Jing
Liu, Tonghua
author_facet Liang, Zhiyong
Zeng, Xuan
Gao, Jie
Wu, Shafei
Wang, Peng
Shi, Xiaohua
Zhang, Jing
Liu, Tonghua
author_sort Liang, Zhiyong
collection PubMed
description BACKGROUND: The EGFR and HER2 genes are located on chromosomes 7 and 17, respectively. They are therapeutic targets in some tumors. The TOP2A gene, which is located near HER2 on chromosome 17, is the target of many chemotherapeutic agents, and co-amplification of HER2 and TOP2A has been described in several tumor types. Herein, we investigated the gene status of EGFR, HER2, and TOP2A in Chinese gastric carcinoma patients. We determined the rate of polysomy for chromosomes 7 and 17, and we attempted to clarify the relationship between EGFR, HER2, and TOP2A gene copy number and increased expression of their encoded proteins. Furthermore, we tried to address the relationship between alterations in EGFR, HER2, and TOP2A and chromosome polysomy. METHODS: One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization (FISH) methods. RESULTS: Forty-two percent of the cases showed EGFR overexpression; 16% showed EGFR FISH positive; 6% showed HER2 overexpression; and 11% showed HER2 gene amplification, including all six HER2 overexpression cases. TOP2A nuclear staining (nuclear index, NI) was determined in all 100 tumors: NI values ranged from 0.5 – 90%. Three percent of the tumors showed TOP2A gene amplification, which were all accompanied by HER2 gene amplification. Nineteen percent of the tumors showed chromosome 7 polysomy, and 16% showed chromosome 17 polysomy. Chromosome 7 polysomy correlated significantly with EGFR FISH-positivity, but was not associated with EGFR overexpression. HER2 overexpression associated significantly with HER2 gene amplification. TOP2A gene amplification was significantly associated with HER2 gene amplification. No relationship was found between alterations in the EGFR, HER2, and TOP2A genes and clinicopathologic variables of gastric carcinoma. CONCLUSION: The data from our study suggest that chromosome 7 polysomy may be responsible for increased EGFR gene copy number in gastric carcinomas, and that HER2 gene amplification may be the major reason for HER2 protein overexpression. A combined investigation of the gene status of EGFR, HER2, and TOP2A should facilitate the identification of a target therapeutic regimen for gastric carcinoma patients.
format Text
id pubmed-2613415
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26134152009-01-03 Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients Liang, Zhiyong Zeng, Xuan Gao, Jie Wu, Shafei Wang, Peng Shi, Xiaohua Zhang, Jing Liu, Tonghua BMC Cancer Research Article BACKGROUND: The EGFR and HER2 genes are located on chromosomes 7 and 17, respectively. They are therapeutic targets in some tumors. The TOP2A gene, which is located near HER2 on chromosome 17, is the target of many chemotherapeutic agents, and co-amplification of HER2 and TOP2A has been described in several tumor types. Herein, we investigated the gene status of EGFR, HER2, and TOP2A in Chinese gastric carcinoma patients. We determined the rate of polysomy for chromosomes 7 and 17, and we attempted to clarify the relationship between EGFR, HER2, and TOP2A gene copy number and increased expression of their encoded proteins. Furthermore, we tried to address the relationship between alterations in EGFR, HER2, and TOP2A and chromosome polysomy. METHODS: One hundred cases of formalin fixed and paraffin embedded tumor tissues from Chinese gastric carcinoma patients were investigated by immunohistochemistry and fluorescence in situ hybridization (FISH) methods. RESULTS: Forty-two percent of the cases showed EGFR overexpression; 16% showed EGFR FISH positive; 6% showed HER2 overexpression; and 11% showed HER2 gene amplification, including all six HER2 overexpression cases. TOP2A nuclear staining (nuclear index, NI) was determined in all 100 tumors: NI values ranged from 0.5 – 90%. Three percent of the tumors showed TOP2A gene amplification, which were all accompanied by HER2 gene amplification. Nineteen percent of the tumors showed chromosome 7 polysomy, and 16% showed chromosome 17 polysomy. Chromosome 7 polysomy correlated significantly with EGFR FISH-positivity, but was not associated with EGFR overexpression. HER2 overexpression associated significantly with HER2 gene amplification. TOP2A gene amplification was significantly associated with HER2 gene amplification. No relationship was found between alterations in the EGFR, HER2, and TOP2A genes and clinicopathologic variables of gastric carcinoma. CONCLUSION: The data from our study suggest that chromosome 7 polysomy may be responsible for increased EGFR gene copy number in gastric carcinomas, and that HER2 gene amplification may be the major reason for HER2 protein overexpression. A combined investigation of the gene status of EGFR, HER2, and TOP2A should facilitate the identification of a target therapeutic regimen for gastric carcinoma patients. BioMed Central 2008-12-06 /pmc/articles/PMC2613415/ /pubmed/19061514 http://dx.doi.org/10.1186/1471-2407-8-363 Text en Copyright © 2008 Liang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liang, Zhiyong
Zeng, Xuan
Gao, Jie
Wu, Shafei
Wang, Peng
Shi, Xiaohua
Zhang, Jing
Liu, Tonghua
Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
title Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
title_full Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
title_fullStr Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
title_full_unstemmed Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
title_short Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients
title_sort analysis of egfr, her2, and top2a gene status and chromosomal polysomy in gastric adenocarcinoma from chinese patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613415/
https://www.ncbi.nlm.nih.gov/pubmed/19061514
http://dx.doi.org/10.1186/1471-2407-8-363
work_keys_str_mv AT liangzhiyong analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients
AT zengxuan analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients
AT gaojie analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients
AT wushafei analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients
AT wangpeng analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients
AT shixiaohua analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients
AT zhangjing analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients
AT liutonghua analysisofegfrher2andtop2agenestatusandchromosomalpolysomyingastricadenocarcinomafromchinesepatients